Big MedTech companies are more and more looking for external projects to invest in. While early-stage companies may detain convincing science and promising ideas, they often lack the means and expertise that big players can offer. How do corporates identify value in early-stage companies? What drives them to choose one project over the other? The options in early-stage partnerships are diverse: licencing, co-development, collaboration… What options are best depending on the nature of the project and the players involved? How to find a convergent interest and build a shared value for both parties? What are the criteria to evaluate the success of these collaborations? How are these strategic partnerships evolving and are there novel models of collaborations emerging?
Moderator: Svetlana Stotskaya, Independent Consultant, Marketing and Brand Strategist 
